Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013

Schnegg-Kaufmann, Annatina; Feller, Anita; Baldomero, Helen; Rovó, Alicia; Manz, Markus G.; Gregor, Michael; Efthymiou, Anna; Bargetzi, Mario; Hess, U.; Spertini, Olivier; Chalandon, Yves; Passweg, Jakob; Stüssi, Georg; Arndt, Volker; Bonadies, Nicolas

doi:10.1016/j.canep.2017.11.008

Cited by 8 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the incidence of AML, which is a long-established entity, was more homogeneous across different regions. Indeed, overall rates were consistent with European 2 , 8 and US 25 findings, as well as with smaller European series 13 , 26 – 28 , while slightly lower rates were reported in Canada 29 and Switzerland 30 . Karyotypic information was not available for many of our cases, and thus, the proportion of AML with cytogenetic abnormalities (14%) was slightly lower in comparison with more specific studies 31 – 33 .…”

Section: Discussionsupporting

confidence: 85%

Incidence of myeloid neoplasms in Spain (2002–2013): a population-based study of the Spanish network of cancer registries

Solans

Sanvisens

Ameijide

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Comprehensive population-based data on myeloid neoplasms (MNs) are limited, mainly because some subtypes were not recognized as hematological cancers prior to the WHO publication in 2001, and others are too rare to allow robust estimates within regional studies. Herein, we provide incidence data of the whole spectrum of MNs in Spain during 2002–2013 using harmonized data from 13 population-based cancer registries. Cases (n = 17,522) were grouped following the HAEMACARE groupings and 2013-European standardized incidence rates (ASRE), incidence trends, and estimates for 2021 were calculated. ASRE per 100,000 inhabitants was 5.14 (95% CI: 5.00–5.27) for myeloproliferative neoplasms (MPN), 4.71 (95% CI: 4.59–4.84) for myelodysplastic syndromes (MDS), 3.91 (95% CI: 3.79–4.02) for acute myeloid leukemia, 0.83 (95% CI: 0.78–0.88) for MDS/MPN, 0.35 (95% CI: 0.32–0.39) for acute leukemia of ambiguous lineage, and 0.58 (95% CI: 0.53–0.62) for not-otherwise specified (NOS) cases. This study highlights some useful points for public health authorities, such as the remarkable variability in incidence rates among Spanish provinces, the increasing incidence of MPN, MDS, and MDS/MPN during the period of study, in contrast to a drop in NOS cases, and the number of cases expected in 2021 based on these data (8446 new MNs).

show abstract

Section: Discussionsupporting

confidence: 85%

Incidence of myeloid neoplasms in Spain (2002–2013): a population-based study of the Spanish network of cancer registries

Solans

Sanvisens

Ameijide

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…These results are confirmed also in the SEER program study [39]. This good result observed in the age class of 65-74 years on a population-based level reflects recent progress made in the management of elderly patients, with increased use of allogeneic hematopoietic stem cell transplantation and access to clinical trials in this age class [38].…”

Section: Discussionsupporting

confidence: 68%

“…This analysis strategy did not show significant differences in 5-year AML NS between the two study periods by either AML subtype or sex for all ages. A previous study based on population-based cancer registries in Switzerland between 2001 and 2013 found modestly improved survival over the period of diagnosis for all ages, with significantly improved outcomes only being seen in patients aged 65-74 years (5-year net survival from 5.2% to 13.5%; p < 0.001) [38]. These results are confirmed also in the SEER program study [39].…”

Section: Discussionsupporting

confidence: 57%

Flexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM

Mounier

Romain

Callanan

et al. 2021

JCM

View full text Add to dashboard Cite

With improvements in acute myeloid leukemia (AML) diagnosis and treatment, more patients are surviving for longer periods. A French population of 9453 AML patients aged ≥15 years diagnosed from 1995 to 2015 was studied to quantify the proportion cured (P), time to cure (TTC) and median survival of patients who are not cured (MedS). Net survival (NS) was estimated using a flexible model adjusted for age and sex in sixteen AML subtypes. When cure assumption was acceptable, the flexible cure model was used to estimate P, TTC and MedS for the uncured patients. The 5-year NS varied from 68% to 9% in men and from 77% to 11% in women in acute promyelocytic leukemia (AML-APL) and in therapy-related AML (t-AML), respectively. Major age-differenced survival was observed for patients with a diagnosis of AML with recurrent cytogenetic abnormalities. A poorer survival in younger patients was found in t-AML and AML with minimal differentiation. An atypical survival profile was found for acute myelomonocytic leukemia and AML without maturation in both sexes and for AML not otherwise specified (only for men) according to age, with a better prognosis for middle-aged compared to younger patients. Sex disparity regarding survival was observed in younger patients with t-AML diagnosed at 25 years of age (+28% at 5 years in men compared to women) and in AML with minimal differentiation (+23% at 5 years in women compared to men). All AML subtypes included an age group for which the assumption of cure was acceptable, although P varied from 90% in younger women with AML-APL to 3% in older men with acute monoblastic and monocytic leukemia. Increased P was associated with shorter TTC. A sizeable proportion of AML patients do not achieve cure, and MedS for these did not exceed 23 months. We identify AML subsets where cure assumption is negative, thus pointing to priority areas for future research efforts.

show abstract

“…Although the World Health Organization recently published a new and more precise classification of AML subtypes [263], very little progress has been made in terms of treatment. According to the Swiss national institute for cancer epidemiology research, the relative cumulative five year survival after AML diagnosis improved modestly between 2001–2007 and 2008–2013 from 19.2% to 23.3% in Switzerland [264]. The median age of AML patients is about 70 years [265] and with the increasing number of elderly people in wealthy countries, the prevalence of AML is expected to increase.…”

Section: Autophagy and Myeloid Tumoursmentioning

confidence: 99%

Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma

Djavaheri-Mergny

Giuriato

Tschan

et al. 2019

Cells

View full text Add to dashboard Cite

Haematopoiesis is a tightly orchestrated process where a pool of hematopoietic stem and progenitor cells (HSPCs) with high self-renewal potential can give rise to both lymphoid and myeloid lineages. The HSPCs pool is reduced with ageing resulting in few HSPC clones maintaining haematopoiesis thereby reducing blood cell diversity, a phenomenon called clonal haematopoiesis. Clonal expansion of HSPCs carrying specific genetic mutations leads to increased risk for haematological malignancies. Therefore, it comes as no surprise that hematopoietic tumours develop in higher frequency in elderly people. Unfortunately, elderly patients with leukaemia or lymphoma still have an unsatisfactory prognosis compared to younger ones highlighting the need to develop more efficient therapies for this group of patients. Growing evidence indicates that macroautophagy (hereafter referred to as autophagy) is essential for health and longevity. This review is focusing on the role of autophagy in normal haematopoiesis as well as in leukaemia and lymphoma development. Attenuated autophagy may support early hematopoietic neoplasia whereas activation of autophagy in later stages of tumour development and in response to a variety of therapies rather triggers a pro-tumoral response. Novel insights into the role of autophagy in haematopoiesis will be discussed in light of designing new autophagy modulating therapies in hematopoietic cancers.

show abstract

Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013

Cited by 8 publications

References 27 publications

Incidence of myeloid neoplasms in Spain (2002–2013): a population-based study of the Spanish network of cancer registries

Incidence of myeloid neoplasms in Spain (2002–2013): a population-based study of the Spanish network of cancer registries

Flexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM

Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma

Contact Info

Product

Resources

About